Financials in USD. Standardized financial statements.
A compact view of how Cyclacel Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $747,000 | $43,000 | $420,000 | $0 | $0 | $0 | $0 | $150,000 | $0 | $843,000 |
| Revenue Growth? | +1637.2% | -89.8% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $609,000 | $0 | $0 | $32,000 | $43,000 | $20,000 | $0 | $4.33M | $32,000 | $9.48M |
| Gross Profit? | $138,000 | $43,000 | $420,000 | -$32,000 | -$43,000 | -$20,000 | -$20,000 | -$4.18M | -$32,000 | -$8.63M |
| Gross Margin? | +18.5% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -2784.7% | 0.0% | -1024.2% |
| Operating Expenses? | $8.56M | $12.05M | $25.87M | $27.66M | $22.39M | $10.64M | $9.68M | $9.70M | $9.49M | $14.99M |
| Operating Income? | -$8.43M | -$12.00M | -$25.45M | -$27.66M | -$22.94M | -$10.64M | -$9.68M | -$9.55M | -$9.49M | -$14.15M |
| EBITDA? | -$8.43M | -$12.00M | -$25.42M | -$27.62M | -$22.69M | -$10.62M | -$9.66M | -$9.52M | -$9.46M | -$14.02M |
| Income Before Tax | -$3.00M | -$11.99M | -$25.55M | -$25.91M | -$22.18M | -$9.68M | -$9.13M | -$8.63M | -$8.46M | -$13.77M |
| Income Tax Expense | -$7,000 | -$782,000 | -$3.00M | -$4.72M | -$3.85M | -$1.24M | -$1.30M | -$1.34M | -$993,000 | -$1.98M |
| Net Income? | -$3.00M | -$11.21M | -$22.55M | -$21.20M | -$18.89M | -$8.45M | -$7.83M | -$7.29M | -$7.47M | -$11.79M |
| EPS? | $-6.45 | $-1.36 | $-28.67 | $-28.50 | $-32.10 | $-12.73 | $-9.64 | $-12.46 | $-18.70 | $-70.35 |
| Diluted EPS? | $-6.45 | $-1.36 | $-28.67 | $-28.50 | $-32.10 | $-12.73 | $-9.64 | $-12.46 | $-18.70 | $-70.35 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality